241 related articles for article (PubMed ID: 32582913)
1. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.
Wang Q; Zhao D; Xian M; Wang Z; Bi E; Su P; Qian J; Ma X; Yang M; Liu L; Zu Y; Pingali SR; Chen K; Cai Z; Yi Q
Blood; 2020 Nov; 136(22):2557-2573. PubMed ID: 32582913
[TBL] [Abstract][Full Text] [Related]
2. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.
Du T; Song Y; Ray A; Chauhan D; Anderson KC
Leukemia; 2021 Feb; 35(2):550-561. PubMed ID: 32424294
[TBL] [Abstract][Full Text] [Related]
4. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.
Ge M; Qiao Z; Kong Y; Liang H; Sun Y; Lu H; Xu Z; Liu H
Br J Cancer; 2021 Feb; 124(4):770-776. PubMed ID: 33250513
[TBL] [Abstract][Full Text] [Related]
5. Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer.
Charan M; Das S; Mishra S; Chatterjee N; Varikuti S; Kaul K; Misri S; Ahirwar DK; Satoskar AR; Ganju RK
Cell Death Dis; 2020 Sep; 11(9):774. PubMed ID: 32943608
[TBL] [Abstract][Full Text] [Related]
6. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway.
Wang C; Zhou X; Li W; Li M; Tu T; Ba X; Wu Y; Huang Z; Fan G; Zhou G; Wu S; Zhao J; Zhang J; Chen J
Cancer Lett; 2017 Sep; 403():271-279. PubMed ID: 28642171
[TBL] [Abstract][Full Text] [Related]
7. Endogenous macrophage migration inhibitory factor reduces the accumulation and toxicity of misfolded SOD1 in a mouse model of ALS.
Leyton-Jaimes MF; Benaim C; Abu-Hamad S; Kahn J; Guetta A; Bucala R; Israelson A
Proc Natl Acad Sci U S A; 2016 Sep; 113(36):10198-203. PubMed ID: 27551074
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
9. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS.
Leyton-Jaimes MF; Kahn J; Israelson A
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14755-14760. PubMed ID: 31262807
[TBL] [Abstract][Full Text] [Related]
10. YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
Xu Y; Fulciniti M; Samur MK; Ho M; Deng S; Liu L; Wen K; Yu T; Chyra Z; Dereibal S; Zhang L; Yao Y; Chakraborty C; Morelli E; Li N; Lopez MA; Perini T; Mu S; An G; Alonso R; Bianchi G; Tai YT; Anderson KC; Qiu L; Munshi NC
Blood; 2020 Jul; 136(4):468-479. PubMed ID: 32187357
[TBL] [Abstract][Full Text] [Related]
11. 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.
Varinelli L; Caccia D; Volpi CC; Caccia C; De Bortoli M; Taverna E; Gualeni AV; Leoni V; Gloghini A; Manenti G; Bongarzone I
Endocr Relat Cancer; 2015 Oct; 22(5):759-75. PubMed ID: 26206776
[TBL] [Abstract][Full Text] [Related]
12. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
13. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
14. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
15. D-dopachrome tautomerase is over-expressed in pancreatic ductal adenocarcinoma and acts cooperatively with macrophage migration inhibitory factor to promote cancer growth.
Guo D; Guo J; Yao J; Jiang K; Hu J; Wang B; Liu H; Lin L; Sun W; Jiang X
Int J Cancer; 2016 Nov; 139(9):2056-67. PubMed ID: 27434219
[TBL] [Abstract][Full Text] [Related]
16. Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
Imaoka M; Tanese K; Masugi Y; Hayashi M; Sakamoto M
Cancer Sci; 2019 Jul; 110(7):2273-2283. PubMed ID: 31069878
[TBL] [Abstract][Full Text] [Related]
17. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
18. MIF Maintains the Tumorigenic Capacity of Brain Tumor-Initiating Cells by Directly Inhibiting p53.
Fukaya R; Ohta S; Yaguchi T; Matsuzaki Y; Sugihara E; Okano H; Saya H; Kawakami Y; Kawase T; Yoshida K; Toda M
Cancer Res; 2016 May; 76(9):2813-23. PubMed ID: 26980763
[TBL] [Abstract][Full Text] [Related]
19. Exosome-Transmitted
Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
[TBL] [Abstract][Full Text] [Related]
20. LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF.
Klasen C; Ziehm T; Huber M; Asare Y; Kapurniotu A; Shachar I; Bernhagen J; El Bounkari O
Cell Signal; 2018 Jun; 46():32-42. PubMed ID: 29476963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
